Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | GPR3 | P46089 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | TNKS | O95271 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.69 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | IDE | P14735 | 1/20 | 0.52 |
| ▸ | MPI | P34949 | 1/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29779876 | 1.00 | PARP1 (0.69) | PARP1KDM4EALDH1A1GPR3HSD17B10 | |
| SCHEMBL29593478 | 0.82 | PARP1 (1.00) | PARP1KDM4EALDH1A1GPR3HSD17B10 | |
| SCHEMBL30090619 | 0.82 | PARP1 (1.00) | PARP1KDM4EALDH1A1GPR3HSD17B10 | |
| SCHEMBL17293 | 0.82 | PARP1 (1.00) | PARP1KDM4EALDH1A1GPR3HSD17B10 | |
| SCHEMBL31326568 | 0.82 | PARP1 (1.00) | PARP1KDM4EALDH1A1GPR3HSD17B10 | |
| Water SCHEMBL11582787 | 0.80 | PARP1 (0.95) | PARP1KDM4EALDH1A1GPR3HSD17B10 | |
| Hydrochloric Acid SCHEMBL30293260 | 0.80 | PARP1 (0.95) | PARP1KDM4EALDH1A1GPR3HSD17B10 | |
| SCHEMBL14355022 | 0.78 | PARP1 (0.75) | PARP1KDM4EALDH1A1GPR3HSD17B10 | |
| SCHEMBL8873438 | 0.78 | PARP1 (0.74) | PARP1KDM4EALDH1A1GPR3HSD17B10 | |
| SCHEMBL1173042 | 0.76 | ALDH1A1 (0.67) | PARP1KDM4EALDH1A1GPR3HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716438-B | Benzo [7,8] indolizine [1,2-c ] quinoline skeleton derivative and synthetic method thereof | 常州大学 | 2023-05-23 | — | — | CN | disclosed |
| CN-114716438-A | Derivative with benzo [7,8] indolizine [1,2-c ] quinoline skeleton and synthetic method thereof | 常州大学 | 2022-07-08 | — | — | CN | disclosed |
| EP-2326645-B9 | COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT | ACRAF (IT) | 2013-04-17 | — | — | EP | disclosed |
| EP-2326645-B1 | COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT | ACRAF (IT) | 2012-11-07 | — | — | EP | disclosed |
| US-20110160201-A1 | COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT | AZIENDE CHIMI. RIUN. ANG. FRANC. A.C.R.A.F. S.p.A. (IT) | 2011-06-30 | — | — | US | disclosed |
| EP-2326645-A1 | COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010012611-A1 | COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2010-02-04 | — | — | WO | disclosed |
| EP-0781282-A1 | [1,2,4]TRIAZOLO[4,3-a]QUINOXALINONE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1997-07-02 | — | — | EP | disclosed |
| WO-1996008493-A1 | [1,2,4]TRIAZOLO[4,3-a]QUINOXALINONE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1996-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160201-A1 | COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT | TPH1, TPH2, HTR1A | PARP1 1485/4885KDM4E 3480/4885ALDH1A1 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.